• Meta analysis using the most serious outcome reported shows 15% [-57‑54%] improvement, without reaching statistical significance. Results are worse for Randomized Controlled Trials and similar for peer-reviewed studies. Results are consistent with early treatment being more effective than late treatment. • 4 studies from 4 independent teams in 2 different countries show statistically significant improvements in isolation (1 for the most serious outcome).• Efficacy is variant dependent. In Vitro studies suggest lower efficacy for omicron BA.1 [Liu, Sheward, VanBlargan] and no efficacy for omicron BA.2 [Zhou]. US EUA has been revoked. Monoclonal antibody use with variants can be associated with prolonged viral loads, clinical deterioration, and immune escape [Choudhary]. • While many treatments have some level of efficacy, they do not replace vaccines and other measures to avoid infection. Only 43% of sotrovimab studies show zero events in the treatment arm. Multiple treatments are typically used in combination, and other treatments are significantly more effective.• No treatment, vaccine, or intervention is 100% available and effective for all variants. All practical, effective, and safe means should be used. Denying the efficacy of treatments increases mortality, morbidity, collateral damage, and endemic risk.• All data to reproduce this paper and sources are in the appendix.